

Partnership and/ or Licensing Opportunities

HLA-G: A NEW MOLECULE FOR BONE RESORPTION TREATMENT

Bone remodelling, is a continuous process by which bone resorption (through osteoclasts) is followed by bone formation (through osteoblasts) for maintaining normal bone mass. The Bone remodelling deregulation causes the development of various bone disorders. Therefore, there is an important need to develop therapeutic strategies for treating or preventing bone disorders like osteoporosis. Here we describe a novel putative therapeutic molecule inhibitor of bone resorption.

Invention:

Use of soluble HLA-G isoform as a molecule for the treatment or prevention of bone resorption.

This invention is the result of the collaboration of two research institutes Etablissement Français du Sang (EFS) and the Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA).


This technology is patented.

Keywords:

Soluble HLA-G, bone remodelling, treatment of bone resorption.

Description:

The inventors showed that HLA-G molecule blocks osteoclastogenesis and promotes bone formation. Data suggest that **HLA-G isoform can be used for treatment or prevention of bone resorption like osteoporosis.**



Applications:

Treatment of clinical disorders of bone resorption, like:

- Osteoporosis
- Paget's disease
- Osteolytic bone tumors
- Osteopenia

Bibliography:

Deschaseaux F et al, FASEB. 04/2013; Naji A et al, stem cells, 08/2013.

CONTACTS:

Research team

Luc Sensebe, PhD
luc.sensebe@efs.sante.fr
Phone: +33 5 61 28 37 60

Frédéric Deschaseaux, PhD
frederic.deschaseaux@efs.sante.fr
Phone: +33 5 61 28 37 74

Technology transfer office

Kenza Belhaj PhD
Head of IP & TT department
kenza.belhaj@efs.sante.fr
Phone: +33 1 55 93 28 35

MAILING:

EFS-Direction de la Valorisation des Innovations

20 avenue du Stade de France
93218 La Plaine Saint Denis,
CEDEX, France
www.dondusang.net

PATENTS:

Granted:

FR 1059653
EP 11797266,1
US 13/989 303
JP 2013-539394
CN 201180056082,6

Pending:

IT, DE, SE, FR, GB, DK, NL,
CH

Reference:

OTEF- 2013.03.05